Cathie Wood’s ARK ETF published their daily trades for Friday, December 19th, 2025, showcasing significant activity in several key stocks. Leading the trades was a substantial sale of 23,110 shares of ...

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best NASDAQ stocks under $10 to buy. As of December 15, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has a ‘Hold’ or equivalent rating from ...

Dec 8 (Reuters) - Recursion Pharma, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Marc Santos is a Guides Staff Writer from the Philippines. He's a seasoned writer with over four years of industry experience, and he is an enjoyer of all things difficult in gaming. If Marc's not ...

We're often accused of doing things backwards. That's why every morning we double-check in the mirror to make sure our shirt is on right. But one thing we do backwards on purpose is parking. If you ...

Nov 18 (Reuters) - Reverse stock splits globally have climbed to a record this year, underscoring the strain on small-cap companies struggling to stay listed even as an AI-fueled rally lifts ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Gizmodo may earn an affiliate commission. Reading time 7 minutes ...

Q3 net loss widens to $365 million from $323 million a year ago Revenue jumps 36% in Q3, but tariffs and costs hit margins Shares drop as much as 17% Nov 12 (Reuters) - Polestar reported a wider third ...